The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Stryker's revenues will grow 3.3% and EPS will increase 10.8%.
The average estimate for revenue is $2.29 billion. On the bottom line, the average EPS estimate is $1.13.
Last quarter, Stryker recorded revenue of $2.05 billion. GAAP reported sales were 1.0% higher than the prior-year quarter's $2.03 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.97. GAAP EPS of $0.92 for Q3 were 9.5% higher than the prior-year quarter's $0.84 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 68.2%, 30 basis points better than the prior-year quarter. Operating margin was 23.0%, 70 basis points worse than the prior-year quarter. Net margin was 17.2%, 110 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $8.61 billion. The average EPS estimate is $4.06.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 1,445 members out of 1,477 rating the stock outperform, and 32 members rating it underperform. Among 470 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 461 give Stryker a green thumbs-up, and nine give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Stryker is outperform, with an average price target of $61.25.
Is Stryker the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Stryker to My Watchlist.